Gemer P 1 Tablet ER is a combination oral antidiabetic medication containing Glimepiride 1 mg, Metformin 500 mg, and Pioglitazone 15 mg, formulated for extended-release administration. This triple-agent therapy is indicated for the management of type 2 diabetes mellitus in patients inadequately controlled by diet, exercise, and monotherapy. Glimepiride, a sulfonylurea, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to enhanced glycemic control without causing significant hypoglycemia. Pioglitazone, a thiazolidinedione, acts as an insulin sensitizer by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), improving insulin sensitivity in adipose tissue, muscle, and the liver. The extended-release formulation allows for once-daily dosing, promoting better patient adherence and stable plasma drug concentrations. Gemer P 1 Tablet ER should be used as part of a comprehensive diabetes management plan including diet, exercise, and regular monitoring of blood glucose and HbA1c levels. Caution is advised in patients with hepatic or renal impairment, heart failure, or risk factors for lactic acidosis. Adverse effects may include hypoglycemia, gastrointestinal disturbances, weight gain, and edema. Regular follow-up with healthcare providers is essential to optimize therapy and minimize risks.